• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017-2023.

作者信息

Kim Donghee, Loomba Rohit, Ahmed Aijaz

机构信息

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.

Division of Gastroenterology and Epidemiology, University of California at San Diego, La Jolla, CA, USA.

出版信息

Clin Mol Hepatol. 2025 Jul;31(3):e235-e238. doi: 10.3350/cmh.2024.1150. Epub 2024 Dec 30.

DOI:10.3350/cmh.2024.1150
PMID:39736264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12260613/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1db/12260613/00f2e5154e2e/cmh-2024-1150f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1db/12260613/00f2e5154e2e/cmh-2024-1150f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1db/12260613/00f2e5154e2e/cmh-2024-1150f1.jpg

相似文献

1
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017-2023.2017 - 2023年美国糖尿病前期和糖尿病成年人中MAFLD、代谢性脂肪性肝病（MAFLD的旧称MetALD）和肝纤维化的当前负担
Clin Mol Hepatol. 2025 Jul;31(3):e235-e238. doi: 10.3350/cmh.2024.1150. Epub 2024 Dec 30.
2
Cause-specific mortality in patients with steatotic liver disease in the United States.美国脂肪性肝病患者的病因特异性死亡率。
J Hepatol. 2025 May 24. doi: 10.1016/j.jhep.2025.05.013.
3
Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes.脂肪性肝病中代谢功能障碍严重程度及其与肝纤维化的相互作用对全因死亡率及多种肝脏和肝外结局的影响
Metabolism. 2025 Sep;170:156306. doi: 10.1016/j.metabol.2025.156306. Epub 2025 May 23.
4
Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community.社区中具有代谢和酒精风险个体的脂肪性肝病患病率、严重程度及决定因素
J Hepatol. 2025 Jul 4. doi: 10.1016/j.jhep.2025.06.020.
5
Steatotic Liver Disease as a Risk Enhancer in the Presence of Metabolic Syndrome.脂肪性肝病作为代谢综合征存在时的风险增强因素。
Eur J Prev Cardiol. 2025 Jun 12. doi: 10.1093/eurjpc/zwaf330.
6
Prevalence of MASLD, Met-ALD, and ALD and Associated Fibrosis Among US Adults: Insights From NHANES 2017 to 2023.美国成年人中代谢相关脂肪性肝病（MASLD）、代谢性酒精性肝病（Met-ALD）、酒精性肝病（ALD）及相关纤维化的患病率：来自2017年至2023年美国国家健康与营养检查调查（NHANES）的见解
J Clin Gastroenterol. 2025 May 28. doi: 10.1097/MCG.0000000000002202.
7
Differences in the incidence of cirrhosis-associated complications between MASLD, MetALD and ALD among patients with decompensated liver cirrhosis.失代偿期肝硬化患者中，非酒精性脂肪性肝病相关肝硬化（MASLD）、代谢相关脂肪性肝病（MetALD）和酒精性肝病（ALD）之间肝硬化相关并发症发生率的差异。
PLoS One. 2025 Jun 26;20(6):e0325673. doi: 10.1371/journal.pone.0325673. eCollection 2025.
8
Extrahepatic Events in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake.代谢功能障碍相关脂肪性肝病患者的肝外事件以及遗传因素和酒精摄入的影响
Hepatol Res. 2025 Jul 1. doi: 10.1111/hepr.14233.
9
Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score.合并代谢相关脂肪性肝病、代谢相关酒精性肝病和酒精性肝病患者的特征及长期死亡率，以及SAFE评分的效用
JHEP Rep. 2024 Jun 3;6(10):101127. doi: 10.1016/j.jhepr.2024.101127. eCollection 2024 Oct.
10
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023.2017 - 2023年美国成年人脂肪性肝病和肝纤维化的当前负担
Clin Mol Hepatol. 2025 Apr;31(2):382-393. doi: 10.3350/cmh.2024.0987. Epub 2024 Nov 29.

引用本文的文献

1
Association of gut microbiota dietary index with metabolic dysfunction-associated steatotic liver disease: the mediating roles of inflammation and body mass index.肠道微生物群饮食指数与代谢功能障碍相关脂肪性肝病的关联：炎症和体重指数的中介作用
Front Nutr. 2025 May 16;12:1573636. doi: 10.3389/fnut.2025.1573636. eCollection 2025.

本文引用的文献

1
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023.2017 - 2023年美国成年人脂肪性肝病和肝纤维化的当前负担
Clin Mol Hepatol. 2025 Apr;31(2):382-393. doi: 10.3350/cmh.2024.0987. Epub 2024 Nov 29.
2
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.瘦人群与非瘦人群中代谢功能障碍相关脂肪性肝病的长期结局及风险修饰因素
Clin Mol Hepatol. 2025 Jan;31(1):74-89. doi: 10.3350/cmh.2024.0631. Epub 2024 Oct 23.
3
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
采用共识命名法的脂肪肝疾病及其分类的全国流行率估计。
Hepatology. 2024 Mar 1;79(3):666-673. doi: 10.1097/HEP.0000000000000604. Epub 2023 Sep 20.
4
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.代谢功能障碍相关脂肪性肝病的批判性评价：两面性现代性的启示。
Clin Mol Hepatol. 2023 Oct;29(4):831-843. doi: 10.3350/cmh.2023.0277. Epub 2023 Aug 25.
5
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患者死亡的原因和风险概况。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S43-S57. doi: 10.3350/cmh.2022.0351. Epub 2022 Nov 22.
6
Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017-2018.2017 - 2018年美国国家健康与营养检查调查（NHANES）中糖尿病前期和糖尿病成年患者的非酒精性脂肪性肝病及肝纤维化患病率
J Gen Intern Med. 2022 Jan;37(1):261-263. doi: 10.1007/s11606-021-06677-w. Epub 2021 Mar 5.
7
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.全球 2 型糖尿病患者非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学：系统评价和荟萃分析。
J Hepatol. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021. Epub 2019 Jul 4.
8
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.肝纤维化无创诊断技术评估非酒精性脂肪性肝病患者肝脏脂肪变及纤维化的准确性。
Gastroenterology. 2019 May;156(6):1717-1730. doi: 10.1053/j.gastro.2019.01.042. Epub 2019 Jan 25.
9
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者肝脏疾病的无创评估。
Gastroenterology. 2019 Apr;156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18.
10
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.振动控制瞬时弹性成像评估非酒精性脂肪性肝病患者的纤维化和脂肪变性。
Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2. doi: 10.1016/j.cgh.2018.04.043. Epub 2018 Apr 26.